KCT0006951尚未招募未知
A Phase II, Single-center, Single-arm trial to evaluate the efficacy of lazertinib in treatment-naive patients for EGFR mutated non-small cell lung cancer with symptomatic or asymptomatic brain metastasis
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18?(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Subjects older than 18 regardless of gender.
- •2) Patients diagnosed as non-small cell lung cancer with brain metastasis
- •3) NSCLC confirmed with EGFR mutation (E19 del, L858R) by pathology or cytology
- •4) ECOG performance within 0 to 2.
- •5) A minimum life expectancy of 3 months.
- •6) The subjects without any previous chemotherapy including EGFR-TKI.
- •However, enrollement is possible if patients only have received adjuvant or neoadjuvant chemotherapy or radiotherapy prior to 12 month of enrollment. Local treatment does not affect inclusion criteria.
- •7) The subject who agreed with effective contraception during the clinical trial period.
排除标准
- •1) evidence of leptomeningeal seeding, spinal cord compression, or intracranial hemorrhage unrelated to cancer.
- •2) Previous or synchronous cancer other than target lung cancer.
- •exception) well controlled non-melanoma skin cancer, cervical cancer, intraductal breast cancer, thyroid cancer. Cured cancer more than 3 years of complete remission.
- •3) Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- •4) Any cardiovascular disease as followed:
- •A History of symptomatic congestive heart failure (CHF) or serious cardiac arrhythmia requiring treatment
- •B. History of myocardial infarction or unstable angina within 6 months of the first dose of study treatment
- •5) corrected QTcB > 480msec in 12-lead EKG
- •6) Known active B viral hepatitis(HBsAg/HBV DNA +), Known C viral hepatitis(HCV RNA +) and/or HIV carrier
- •7) Women who are pregnant or lactating, or who have a positive pregnancy test before enrollment in the clinical trial
- •8) Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing the product, or past significant bowel resection that may interfere with the proper absorption of the investigational product.
- •9) History of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
- •10) Patients with uncontrolled infectious disease
- •However, infectious diseases that require parenteral antibiotic administration are excluded, but participation is possible after the infection is completely resolved or controlled.
- •11) Patients unable to undergo brain MRI or CT examination
- •12) Patients with a history of hypersensitivity to Lazertinib or its components
- •13) Patients who have administered other investigational drugs within 30 days prior to trial administration
- •14) Those who are unable to participate in the clinical trial under the judgment of the investigator, such as when it is difficult to comply with the procedures, restrictions, and requirements of the clinical trial protocol, or if there is no will to follow follow-up management
- •15) Inadequate bone marrow reserve or organ function as a result of any of the following tests:
- •Absolute neutrophil count (ANC) < 1.5 x 109/L
- •Platelet count < 100 x 109/L
- •Hemoglobin < 9.0 g/dL
- •Alanine aminotransferase (ALT) > 2.5 times the upper limit of normal (ULN) if liver metastases cannot be demonstrated, or > 5x ULN if liver metastases are present
- •Aspartate aminotransferase (AST) > 2.5x ULN if liver metastases cannot be demonstrated, or > 5x ULN if liver metastases are present.
- •Total bilirubin > 1.5x ULN in the absence of liver metastases, or > 3x ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases
- •Serum creatinine > 1.5x ULN, and creatinine clearance < 50 ml/min as determined by laboratory standard methods (eg Cockcroft and Gault equation)
- •Confirmation of creatinine clearance is only necessary if creatinine > 1.5x ULN.
研究者
相似试验
进行中（未招募）
1 期
Study of the efficacy and safety of the Bintrafusp alfa (M7824) in previously treated cancer called malignant pleural mesothelioma.EUCTR2020-004902-67-ESFundación GECP47
进行中（未招募）
1 期
Clinical trial to evaluate the safety and immune activation of DCVAC/PCa and ONCOS-102 in men with metastatic prostate cancer.advanced metastatic castration-resistant prostate cancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004314-15-CZSOTIO a.s.15
进行中（未招募）
1 期
A clinical study exploring the effect of osimertinib and radiation therapy, in people with newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Treatment naïve patients with synchronous, oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC with or without T790M resistance mutationMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004114-35-NLETOP IBCSG Partners Foundation60
进行中（未招募）
1 期
A clinical study exploring the effect of osimertinib and radiation therapy, in people with newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene.Treatment naïve patients with synchronous, oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC with or without T790M resistance mutationMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004114-35-ESEuropean Thoracic Oncology Platform (ETOP)60
撤回
2 期
A multicentre single-arm phase II trial assessing the safety and efficacy of first-line osimertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancerlungcancerNon small cell lung cancer10038667NL-OMON54434ETOP IBCSG Partners Foundation10